Antia Laboratories Inc.

New products

No new product at this time

BMS-387032 (SNS-032)


Please contact us for quotation and availability

CAS Number: 345627-80-7

Molecular Formula: C17H24N4O2S2

Molecular Weight: 379.54

Solubility: Soluble in distilled water

Purity: 98%+

Biological Activity:

SNS-032 (formerly BMS-387032) is a small-molecule cyclin-dependent kinase (CDK) inhibitor currently in phase I clinical trials for the treatment of B-cell malignancies and advanced solid tumors.Preclinical studies have shown that SNS-032 is a specific and potent inhibitor of CDK2, 7 and 9 which induces cell cycle arrest and apoptosis in tumor cell lines. It was shown to inhibit in vitro angiogenesis and prostaglandin E2 (PGE2) production, both strongly associated with tumorigenesis. Phase I clinical trials support the safety and tolerability of SNS-032 as evaluated in dose-escalation studies. BMS-387032 is currently administered by i.v. infusion but has shown promising potential for oral delivery.


1. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.  Full text

2. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol (2009) 64:723–732 Full text

The product is only for R&D purpose,not for human use.We will not take any responsibility for illegal use.